20 Countries with Free Health Care

In This Article:

In this article, we will be taking a look at the 20 countries with free health care. To skip our detailed analysis, you can go directly to see the 5 countries with free health care.

The U.S. is one of the only advanced countries in the world to not have free healthcare, which is said to cost the country trillions of dollars. According to Public Citizen, if Medicare for All is not implemented, the Federal government will end up spending $42.9 trillion on healthcare in just the next decade alone. The primary reason behind this is that health insurance is generally tied to a person's employment in the U.S., because of which attempts to make healthcare free have failed consistently. The individual healthcare market in the U.S. is worth an astonishing $1.68 trillion. On the other hand, Europe is home to the most countries with free healthcare.

The healthcare industry is one of the most valuable and important sectors in the world, not just in terms of direct value but also in the indirect value it generates by improving the standard of living in a country. In fact, it was because of healthcare advancements that the world was able to emerge so quickly from the Covid-19 pandemic. At the same time, the pandemic has revolutionized the healthcare industry which is changing rapidly, especially in terms of new technology and innovation.

20 countries with free healthcare
20 countries with free healthcare

A healthcare professional discussing a treatment plan with a patient in an outpatient clinic.

According to Deloitte, one of the ways that the healthcare industry is changing is virtual health delivery. One way that the pandemic has changed lives on every level is through increased remote interaction, initially out of necessity and then out of efficiency and cost-effectiveness. While this doesn't mean that in-person care is being replaced, it will provide new methods of care delivery, and will allow for a reach far greater than what has been possible before, especially in remote areas where there are barely any doctors or healthcare facilities available. The first step in this is electronic health records, followed by using many different digital and tech innovations including machine learning and cloud computing to cut costs and alleviate the shortage of physicians, even in countries with free healthcare as population needs outweigh the number of healthcare staff available in many such countries, including in the UK, whose National Health Service is currently in a crisis due to lack of staff and low payment.

Most of the most profitable pharmaceutical companies in the world have started to incorporate digital and tech solutions in the products and services they provide. This was mentioned by Johnson & Johnson (NYSE:JNJ) in its Q2 2023 earnings call, where it mentioned the pivot to tech solutions stating "This was a strong quarter for Johnson & Johnson with market-leading performance, important advances across our innovative pharmaceutical and medtech pipelines, and a successful initial public offering of Kenvue. We delivered solid sales and earnings growth for the second quarter of 2023, reporting operational sales of 7.5% and adjusted operational EPS growth of 9.7%. These strong results contributed to our confidence in raising our expectations for this year. You may have seen this morning the announcement that we intend to split of Kenvue shares through an exchange offer as the next step in the separation of Kenvue. Joe will provide additional information later in the call. We are excited about entering a new era for Johnson & Johnson, one built around science, innovation, and technology, and strategically focused on pharmaceutical medtech while maintaining our position as the world's largest, most diversified healthcare products company with 25 platforms over $1 billion in annual sales. And on today's call, I would like to share recent highlights and achievements from across the business that have contributed to our year-to-date results, as well as upcoming catalysts that give me great confidence in our near and long-term future performance. Starting with medtech. For the second quarter of 2023, we generated 14.7% operational and 9.9% adjusted operational growth, which excludes the impact of the Abiomed acquisition. On a pro forma basis, using sales publicly reported by Abiomed prior to our acquisition, medtech grew 10.2%. These strong results continue to show that our efforts to improve the growth of the medtech business are working."